Dec. 18, 2006 -- One month after the FDA approved the return of silicone gel-filled breast implants to the U.S. market, a European study is raising new concerns about their safety.
Researchers in Austria have identified proteins that accumulate on the surface of silicone breast implants, which they say could be the cause of immune reactions in women who have them.
The FDA ordered silicone-gel filled breast implants off the market in 1992 after a flurry of complaints that they caused autoimmune illnesses and even.
Thousands of women sued implant maker Dow Corning, and settlements forced the company into bankruptcy.
But on Nov. 17, the FDA approved the request of two other companies to begin marketing the implants, stating that research shows "no convincing evidence" breast implants cause either connective tissue autoimmune disease or cancer.
"The extensive body of scientific evidence provides reasonable assurance of the benefits and risks of these devices," FDA director for devices and radiological health Daniel Schultz, MD, said in a news release at the time.
Findings Raise New Questions
In the newly-reported Austrian study, researchers showed that key proteins accumulate on the surface of silicone breast implants long after the implants are placed in the body. They were able to do this using a relatively new, targeted research method known as proteomics.
These proteins provide a link between silicone implants and autoimmune disease, says lead researcher Aleksandar Backovic, of Austria's Innsbruck Medical University.
"We believe this is at least one of the causes of the immune system problems that have been attributed to silicone implants," Backovic tells WebMD.
Further study revealed the reaction is likely to occur many years, and even decades, after implantation, rather than weeks or months later. Backovic says this could explain why earlier research failed to identify the protein adherence.
The study appears in the December issue of the American Chemical Society publication, Journal of Proteome Research.
Implants Extensively Studied
In allowing the return of silicone-filled breast implants to the U.S. market, the FDA noted they were among "the most extensively studied medical devices."